Cancer Currents: An NCI Cancer Research Blog
A blog featuring news and research updates from the National Cancer Institute.
-
The FDA has approved carfilzomib in combination with other anticancer drugs to treat patients with relapsed multiple myeloma.
-
The FDA last month approved gefitinib (Iressa) for the treatment of some patients with lung cancer, marking the drug’s return to the U.S. market after an earlier withdrawal.
-
A single injection of a gene therapy viral vector inhibited tumor growth of some mouse tumors derived from patients with recurrent ovarian cancer.
-
Many patients with cancer and their physicians are not communicating about the patients’ preferences for end-of-life medical care, a new study suggests.
-
In July 2015, the NCI’s cancer centers program expanded by adding a new institution and awarding the comprehensive designation to four existing NCI-designated cancer centers.
-
NCI periodically provides updates on new websites and other online content of interest to the cancer community.
-
NCI has released a new funding announcement to stimulate research on optimal smoking cessation approaches delivered in conjunction with lung cancer screening.
-
Study estimates about 1.6 million fewer women and 400,000 fewer men tan indoors, but it’s still a common practice.
-
In a large clinical trial, the oncolytic virus therapy T-VEC improved the durable response rate and median survival in patients with advanced melanoma.
-
NCI recently convened a workshop to discuss the status of genomic characterization for childhood cancers and to identify opportunities for future research.